De Novo Mutations in EIF2B1 Affecting eIF2 Signaling Cause Neonatal/Early-Onset Diabetes and Transient Hepatic Dysfunction.
Elisa De FrancoRichard CaswellMatthew B JohnsonMatthew N WakelingAmnon ZungVũ Chí DũngCấn Thị Bích NgọcRajiv GoonetillekeMaritza Vivanco JuryMohammed El-KhateebSian EllardSarah E FlanaganDavid RonAndrew T HattersleyPublished in: Diabetes (2019)
Permanent neonatal diabetes mellitus (PNDM) is caused by reduced β-cell number or impaired β-cell function. Understanding of the genetic basis of this disorder highlights fundamental β-cell mechanisms. We performed trio genome sequencing for 44 patients with PNDM and their unaffected parents to identify causative de novo variants. Replication studies were performed in 188 patients diagnosed with diabetes before 2 years of age without a genetic diagnosis. EIF2B1 (encoding the eIF2B complex α subunit) was the only gene with novel de novo variants (all missense) in at least three patients. Replication studies identified two further patients with de novo EIF2B1 variants. In addition to having diabetes, four of five patients had hepatitis-like episodes in childhood. The EIF2B1 de novo mutations were found to map to the same protein surface. We propose that these variants render the eIF2B complex insensitive to eIF2 phosphorylation, which occurs under stress conditions and triggers expression of stress response genes. Failure of eIF2B to sense eIF2 phosphorylation likely leads to unregulated unfolded protein response and cell death. Our results establish de novo EIF2B1 mutations as a novel cause of permanent diabetes and liver dysfunction. These findings confirm the importance of cell stress regulation for β-cells and highlight EIF2B1's fundamental role within this pathway.
Keyphrases
- end stage renal disease
- early onset
- cardiovascular disease
- copy number
- type diabetes
- chronic kidney disease
- ejection fraction
- newly diagnosed
- cell death
- single cell
- genome wide
- prognostic factors
- stem cells
- patient reported outcomes
- oxidative stress
- small molecule
- cell therapy
- protein kinase
- autism spectrum disorder
- intellectual disability
- young adults
- stress induced
- transcription factor
- case control
- protein protein